What was the overall valuation of the US brachytherapy market in 2024?

The overall market valuation was $262.15 Million in 2024. Read More

What is the projected market valuation for the US brachytherapy market by 2035?

The projected valuation for 2035 is $542.89 Million. Read More

What is the expected CAGR for the US brachytherapy market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 6.84%. Read More

Which application segment had the highest valuation in 2024?

Prostate cancer had the highest valuation at $80.54 Million in 2024. Read More

What are the projected valuations for the Low-Dose Rate segment by 2035?

The projected valuation for the Low-Dose Rate segment is $210.0 Million by 2035. Read More

Which procedure type is expected to show significant growth in the US brachytherapy market?

Interstitial brachytherapy is expected to show significant growth, with a valuation of $170.0 Million projected for 2035. Read More

What is the market valuation for ambulatory surgical centers in 2024?

The market valuation for ambulatory surgical centers was $70.0 Million in 2024. Read More

Which key player is based in the US and is involved in the brachytherapy market?

Varian Medical Systems is a key player based in the US involved in the brachytherapy market. Read More

What is the projected valuation for the High-Dose Rate segment by 2035?

The projected valuation for the High-Dose Rate segment is $250.0 Million by 2035. Read More

How does the market for gynecological cancers compare to that of breast cancer in 2024?

In 2024, the market for breast cancer was valued at $60.16 Million, while gynecological cancers were valued at $45.16 Million. Read More

US Brachytherapy Market

ID: MRFR/MED/14510-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Brachytherapy Market Research Report: Size, Share, Trend Analysis By Applications (Prostate Cancer, Breast Cancer, Gynecological Cancers, Skin Cancer, Lung Cancer), By Types (Low-Dose Rate, High-Dose Rate, Pulse Dose Rate), By Procedure Type (Interstitial Brachytherapy, Intracavitary Brachytherapy, Surface Brachytherapy) and By End Use (Hospitals, Ambulatory Surgical Centers, Radiation Oncology Centers) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Application (USD Million)
  1. 4.1.1 Prostate Cancer
  2. 4.1.2 Breast Cancer
  3. 4.1.3 Gynecological Cancers
  4. 4.1.4 Skin Cancer
  5. 4.1.5 Lung Cancer
2. 4.2 Pharmaceutical, BY Type (USD Million)
  1. 4.2.1 Low-Dose Rate
  2. 4.2.2 High-Dose Rate
  3. 4.2.3 Pulse Dose Rate
3. 4.3 Pharmaceutical, BY Procedure Type (USD Million)
  1. 4.3.1 Interstitial Brachytherapy
  2. 4.3.2 Intracavitary Brachytherapy
  3. 4.3.3 Surface Brachytherapy
4. 4.4 Pharmaceutical, BY End Use (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Ambulatory Surgical Centers
  3. 4.4.3 Radiation Oncology Centers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Elekta AB (SE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Varian Medical Systems (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Brachytherapy Solutions (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 CIVCO Medical Solutions (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Isoray Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Nucletron (NL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Accuray Incorporated (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Boston Scientific Corporation (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY PROCEDURE TYPE
5. 6.5 US MARKET ANALYSIS BY END USE
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY PROCEDURE TYPE, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY PROCEDURE TYPE, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USE, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY PROCEDURE TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Application (USD Million, 2025-2035)

Prostate Cancer
Breast Cancer
Gynecological Cancers
Skin Cancer
Lung Cancer

Pharmaceutical By Type (USD Million, 2025-2035)

Low-Dose Rate
High-Dose Rate
Pulse Dose Rate

Pharmaceutical By Procedure Type (USD Million, 2025-2035)

Interstitial Brachytherapy
Intracavitary Brachytherapy
Surface Brachytherapy

Pharmaceutical By End Use (USD Million, 2025-2035)

Hospitals
Ambulatory Surgical Centers
Radiation Oncology Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”